



## Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

February 14, 2018

VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins, Executive Vice President and Chief Financial Officer, is leaving the Company but will remain available on a consulting basis. Koert VandenEnden, Arbutus' Vice President of Finance, will serve as Interim Chief Financial Officer. The Company will promptly begin a search for a permanent Chief Financial Officer.

"We would like to thank Bruce for his dedicated service to Arbutus over the past 4 years and wish him the very best in his professional endeavors," said Dr. Mark J. Murray, Arbutus' President and CEO. "Having recently completed the \$116mm financing with Roivant Sciences the Company's balance sheet is strong and the Company has recently announced the consolidation of the business to Warminster, PA, both of which represent important factors in this decision."

### About Arbutus

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### Investors

Mark Murray  
President and Chief Executive Officer  
Phone: 604-419-3200  
Email: [mmurray@arbutusbio.com](mailto:mmurray@arbutusbio.com)

Tiffany Tolmie  
Manager, Investor Relations  
Phone: 604-419-3200  
Email: [ttolmie@arbutusbio.com](mailto:ttolmie@arbutusbio.com)

#### Media

David Schull  
Russo Partners  
Phone: 858-717-2310  
Email: [david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

 [Primary Logo](#)

Source: Arbutus Biopharma Corporation